^
    Back
    Association details:
    Biomarker:CD20 overexpression
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen:R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2021
    Title:

    095 | Highly Multiplex Tissue Imaging of DLBCL Identifies Novel Pathological Features Predictive of Overall Survival

    Published date:
    06/09/2021
    Excerpt:
    ...to evaluate the prognostic significance of immune markers in R-CHOP treated DLBCL….high CD20 expression was found to be significantly associated with superior OS (HR = 0.57; p < 0.05)
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    The Novel HDAC Inhibitor Chidamide Synergizes with Rituximab to Inhibit DLBCL Tumor Growth in Vitro and In Vivo By up-Regulating CD20 Expression

    Published date:
    11/01/2018
    Excerpt:
    In R-CHOP treated cohort (n=233), higher expression of CD20 expression (n=137) is significantly associated with superior clinical outcomes compared with lower CD20 expression (n=96) with P=0.0038, HR=0.4753, 95% CI=0.274-0.779.
    DOI:
    10.1182/blood-2018-99-114598